Medigus Ltd. (MDGS): Price and Financial Metrics


Medigus Ltd. (MDGS): $1.58

0.03 (+1.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MDGS POWR Grades


  • MDGS scores best on the Sentiment dimension, with a Sentiment rank ahead of 76.4% of US stocks.
  • MDGS's strongest trending metric is Growth; it's been moving up over the last 48 weeks.
  • MDGS's current lowest rank is in the Quality metric (where it is better than 2.69% of US stocks).

MDGS Stock Summary

  • With a market capitalization of $25,631,862, Medigus Ltd has a greater market value than merely 3.16% of US stocks.
  • MDGS's price/sales ratio is 48.27; that's higher than the P/S ratio of 94.66% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MDGS comes in at -71.63% -- higher than that of only 3.72% of stocks in our set.
  • Stocks that are quantitatively similar to MDGS, based on their financial statements, market capitalization, and price volatility, are HYRE, YEXT, IRTC, WRAP, and RCON.
  • MDGS's SEC filings can be seen here. And to visit Medigus Ltd's official web site, go to www.medigus.com.

MDGS Valuation Summary

  • MDGS's EV/EBIT ratio is -0.3; this is 101.02% lower than that of the median Healthcare stock.
  • Over the past 74 months, MDGS's price/sales ratio has gone up 3.4.
  • MDGS's EV/EBIT ratio has moved up 2.8 over the prior 74 months.

Below are key valuation metrics over time for MDGS.

Stock Date P/S P/B P/E EV/EBIT
MDGS 2021-08-31 45.6 1.1 -3.5 -0.3
MDGS 2021-08-30 42.6 1.0 -3.3 0.0
MDGS 2021-08-27 43.5 1.0 -3.4 -0.1
MDGS 2021-08-26 44.1 1.0 -3.4 -0.2
MDGS 2021-08-25 45.6 1.1 -3.5 -0.3
MDGS 2021-08-24 45.0 1.0 -3.5 -0.2

MDGS Growth Metrics

  • Its year over year price growth rate is now at 23.57%.
  • Its 5 year net cashflow from operations growth rate is now at 11.55%.
  • Its 2 year revenue growth rate is now at 21.79%.
MDGS's revenue has moved up $258,000 over the prior 12 months.

The table below shows MDGS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 0.531 -6.143 -6.85
2019-12-31 0.273 -2.757 -14.178
2018-12-31 0.436 -4.253 -6.598
2017-12-31 0.467 -4.659 -2.545
2016-12-31 0.549 -9.255 -9.007
2015-12-31 0.623328 -6.945102 -9.54729

MDGS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MDGS has a Quality Grade of F, ranking ahead of 0.06% of graded US stocks.
  • MDGS's asset turnover comes in at 0.023 -- ranking 162nd of 183 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows MDGS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.023 -0.947 -1.494
2019-12-31 0.022 -0.667 -12.213
2018-12-31 0.047 -0.392 -4.972
2017-12-31 0.078 -0.105 -1.353
2016-12-31 0.065 0.679 -60.057
2015-12-31 0.047 0.556 -8.106

MDGS Stock Price Chart Interactive Chart >

Price chart for MDGS

MDGS Price/Volume Stats

Current price $1.58 52-week high $4.19
Prev. close $1.55 52-week low $1.27
Day low $1.50 Volume 238,800
Day high $1.58 Avg. volume 2,314,227
50-day MA $1.52 Dividend yield N/A
200-day MA $2.00 Market Cap N/A

Medigus Ltd. (MDGS) Company Bio


Medigus Ltd. develops endoscopic procedures and devices for the treatment of gastroesophageal reflux disease.


MDGS Latest News Stream


Event/Time News Detail
Loading, please wait...

MDGS Latest Social Stream


Loading social stream, please wait...

View Full MDGS Social Stream

Latest MDGS News From Around the Web

Below are the latest news stories about Medigus Ltd that investors may wish to consider to help them evaluate MDGS as an investment opportunity.

Medigus Ltd. Announces Record High Financial Results

Revenues for the first half of 2021 increased by ~3,178% with first ever net profit of approximately $8 million OMER, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today its financial results for the first six months ended June 30, 2021. Revenues for the six-month period ended June 30, 2021, reached a record high, and totale

Yahoo | September 20, 2021

Medigus: Revoltz Commenced Prototype Manufacturing of its Micro-mobility Vehicle

Revoltz Model One is a micro-mobility vehicle for last mile and food delivery.OMER, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that Revoltz, its EV joint venture (19.9% owned), has begun the prototype manufacturing of its micro mobility vehicle. The production has commenced in China together with Mr. Weijian Zhou, o

Yahoo | September 13, 2021

Medigus: Polyrizon to Test its Product Candidate for Protection Against High Transmissible Corona Virus Delta Variant B.1.617.2

In recent pre- clinical studies, Polyrizon products showed strong potential in preventing human coronavirus 229E and Influenza Virus H1N1 from interacting with epithelial host cells and by inhibiting cells' death.OMER, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Med

Yahoo | September 9, 2021

Medigus: Polyrizon Submits a Patent Application for Prevention of Pathogens such as Coronavirus and Allergens from Affecting Nasal Tissue

In recent pre- clinical studies, Polyrizon products showed strong potential by preventing coronavirus and Influenza Virus H1N1 from interacting with epithelial host cells and by inhibiting cells' death. OMER, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Medigus owns

Yahoo | September 2, 2021

Medigus: Gix Media to Acquire 70% of Leading Innovative Media-Tech Company Cortex Group for Approximately $11 Million

Gix Internet finished the first six months of 2021 with revenues of ~$ 16.4 million, Cortex Group Revenues for the first six months of 2021 amounted to ~$ 12.3 million OMER, Israel, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today

Wallstreet:Online | August 31, 2021

Read More 'MDGS' Stories Here

MDGS Price Returns

1-mo 8.22%
3-mo -12.71%
6-mo -27.19%
1-year 22.48%
3-year -53.39%
5-year -96.96%
YTD -17.28%
2020 9.77%
2019 -33.08%
2018 -50.76%
2017 -76.84%
2016 -78.73%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.987 seconds.